Experimental drug aims to prevent bleeding veins in fatty liver disease

NCT ID NCT04365868

Prevention Sponsor: Galectin Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tested a drug called belapectin to see if it could prevent the formation of esophageal varices (enlarged veins in the esophagus) in people with NASH cirrhosis and signs of high blood pressure in the liver. The trial enrolled 357 adults and compared belapectin to a placebo over 78 weeks. However, the study was terminated early, so the final results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: belapectin (GR-MD-02)
What this could lead to: If successful, belapectin could offer a way to prevent dangerous esophageal varices in people with NASH cirrhosis, reducing the risk of life-threatening bleeding.
What could go wrong: The trial was terminated early, so we don't have full results. It's unclear if belapectin works better than placebo, and the study was relatively small (357 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

357 people

The number who actually took part.

Started

Jun 2020

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Each subject must meet all of the following criteria to be enrolled in this study: 1. Is male or female, ≥ 18 and ≤ 75 years of age at the time of Screening. 2. Is willing and able to provide written informed consent prior to the initiation of any study-specific procedures. 3. Has evidence of portal hypertension, with either one of the following: 1. platelet count \<150,000/mm3 OR 2. documented hepatic venous pressure gradient (HVPG) measurement \>6 mmHg OR 3. at least two of the following: * spleen size ≥14 cm (documented by ultrasound, MRI, or CT scan) * abdominal collateral circulation (documented by ultrasound, MRI, or CT scan or physical examination, ie, caput medusae) * documented liver transient elastography (eg, FibroScan) ≥20 kilopascals (kPa). * aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>1. 4. Has a history confirming nonalcoholic steatohepatitis (NASH) cirrhosis, with at least one of the following: * There is a historical liver biopsy showing cirrhosis with steatohepatitis. There is no evidence for a competing etiology for the cirrhosis. * There is a historical liver biopsy showing steatohepatitis, and there is evidence of cirrhosis from clinical or imaging data or a second liver biopsy showing cirrhosis without all features of NASH (as the histological NASH lesions may have burnt out). There is no evidence for a competing etiology. There is at least 1 co-existing metabolic comorbidity at Screening: obesity (with either body mass index \[BMI\] ≥30 kg/m2 or waist circumference ≥102 cm \[40 in, men\] or ≥88 cm \[35 in, women\], or by ethnically appropriate cutpoints); hypertension (either on anti hypertensive drug therapy for at least 1 year or systolic/diastolic blood pressure (BP) \>140/80 mm Hg); Type 2 diabetes (glycated hemoglobin \[HbA1c\] ≥6.5%, or on anti-diabetic medication for at least 1 year); or dyslipidemia (triglycerides ≥150 mg/dL or on drug therapy for hypertriglyceridemia for at least 6 months; high-density lipoprotein cholesterol ≤40 mg/dL \[men\] or ≤50 mg/dL \[women\]) to corroborate a diagnosis of nonalcoholic fatty liver disease (NAFLD). * There is a historical liver biopsy showing cirrhosis with steatosis but not steatohepatitis. There is no evidence for a competing etiology. There are at least 2 co-existing (or history of) metabolic comorbidities (with obesity or diabetes being one of them) to corroborate a diagnosis of NAFLD. * There is a historical liver biopsy showing steatosis but now with cirrhosis either by clinical examination, imaging, or biopsy. If there is a current biopsy, it does not show evidence of steatosis or steatohepatitis as histological lesions may have burned out. There is no evidence for a competing etiology. There are at least 2 co existing (or history of) metabolic comorbidities (with obesity or diabetes being one of them) to corroborate a diagnosis of NAFLD. * Patient with cirrhosis with current or previous imaging showing steatosis. There is no liver histology available. There is no evidence for a competing etiology. There are at least two co-existing or history of metabolic comorbidities with obesity or diabetes being one of them to corroborate a diagnosis of NAFLD. * For patients not meeting the above mentioned criteria, a screening liver biopsy is necessary. Note: All liver biopsy blocks and/or slides for eligibility assessments (including those from historical biopsies) will be reviewed by the central study pathologist while the subject is in Screening. Results from the central study pathologist must be available before the subject is randomized. 5. Absence of hepatocellular carcinoma (HCC) by valid imaging (eg, ultrasound, CT scan, or MRI) within 6 months prior to randomization. If no such imaging result is available, then ultrasound imaging should be performed as part of standard of care. 6. Patients with diabetes mellitus can be enrolled, if they are adequately controlled on a stable dose or doses of antidiabetic medication(s) for at least 3 months before Screening, and their screening HbA1c is ≤9.5%. 7. Patients on vitamin E or pioglitazone can be enrolled if they are on a stable dose and regimen for at least 3 months before screening, and the dose is expected to be held constant during the trial. 8. Patients on a statin can be enrolled if they are on a stable regimen for at least 3 months before Screening, and expected to be held stable during the trial. 9. Is not pregnant and must have a negative serum pregnancy test result prior to randomization. 10. Is of non-childbearing potential or if a fertile man or woman participating in heterosexual relations, agrees to use two acceptable means of contraception (ie, 2 effective methods of contraception, one of which must be a physical barrier method \[eg, male or female condom, diaphragm\] when combined with a highly effective method of contraception \[ie, a method with a failure rate of \<1% per year when used consistently and correctly\]) throughout his/her participation in this study and for 90 days after discontinuation of study treatment. Highly effective forms of contraception include: * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (such as oral, intravaginal, transdermal) methods * progestogen-only hormonal contraception associated with inhibition of ovulation (such as oral, injectable, implantable) * hormone-releasing intrauterine system (IUS) * intrauterine device (IUD) * bilateral tubal occlusion * a vasectomized partner, provided that partner is the sole sexual partner of the women of childbearing potential trial participant and that the vasectomized partner has received medical assessment of the surgical success * sexual abstinence (ie, a refraining from heterosexual intercourse during the entire period of the clinical trial, if it is the preferred and usual lifestyle of the subject). Surgically sterile males and females are not required to use contraception provided they have been considered surgically sterile for at least 6 months. Surgical sterility includes history of surgically successful vasectomy, hysterectomy, or bilateral salpingo-oophorectomy. Postmenopausal women who have been amenorrheic for at least 2 years at the time of Screening will be considered sterile. 11. If a lactating woman, agrees to discontinue nursing before the start of study treatment and refrain from nursing until 90 days after the last dose of study treatment. 12. If a man, agrees to refrain from sperm donation throughout the study period and for a period of 90 days following the last dose of investigational medicinal product (IMP). Female subjects may not begin a cycle of ova donation or harvest throughout the study period and for a period of 90 days following the last dose of IMP. Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Presence of esophageal, gastroesophageal, or isolated gastric varices, based on an upper gastrointestinal (GI) esophagogastroduodenoscopy (EGD) exam conducted during Screening. Patients with portal hypertensive gastropathy could be enrolled. 2. History of hepatic cirrhosis decompensation including any episode of variceal bleeding, ascites not controlled by medication, spontaneous bacterial peritonitis or overt hepatic encephalopathy (West Haven grade ≥2 as assessed by the principal investigator), OR develops signs of hepatic cirrhosis decompensation during Screening. 3. Known or suspected abuse of alcohol (\>20 g/day for women or \>30 g/day for men \[on average per day\]), as per medical history. Significant alcohol consumption is defined as more than 20 grams per day in females and more than 30 grams per day in males. On average, a standard drink in the United States is considered to be 14 grams of alcohol, equivalent to 12 fluid ounces of regular beer (5% alcohol), 5 fluid ounces of table wine (12% alcohol), or 1.5 fluid ounces of 80 proof spirits (40% alcohol). 4. Alcohol dependence (ie, a score \>8 on the Alcohol Use Disorders Identification Test) 5. Narcotics or any other drug abuse or dependence in the last 5 years 6. Prior trans-jugular intrahepatic portal-systemic (TIPS) shunt procedure 7. Documented causes of liver disease other than NASH, including but not restricted to: * Viral hepatitis, unless eradicated at least 3 years prior to Screening * acute hepatitis A infection (presence of hepatitis A immunoglobulin M \[IgM\] at Screening) * positive hepatitis B surface antigen * positive hepatitis C virus (HCV) ribonucleic acid (to be performed prior to randomization in case of positive HCV antibody) * Documented drug-induced liver disease * Alcoholic liver disease * Autoimmune hepatitis * Wilson's disease * Hemochromatosis * Primary biliary cholangitis * Primary sclerosing cholangitis * Genetic hemochromatosis * History or planned liver transplantation * Alpha-1 antitrypsin deficiency 8. History of human immunodeficiency virus (HIV), or positive HIV test at Screening 9. Any of the following test or score: * serum alanine aminotransferase (ALT) \> 5 × upper limit of normal (ULN)\* * serum aspartate aminotransferase (AST) \> 5 × ULN\* \*Screening values will be obtained at Screening Visit 1 (SV1) and Screening Visit 2(SV2) (which will be separated by 2 to 4 weeks). A second screening value that is \>50% higher than the first value should prompt re-evaluation of the severity of the underlying liver disease and eligibility for this trial. If a transaminase level at SV2 is \>33% different from the level at SV1, then additional measurements should be performed at Screening Visit 3 (SV3). In such cases, the baseline transaminase levels will be established for subjects using the mean value of 4 evaluations \[ie, at SV1, SV2, SV3, and Baseline (ie, pre-dose during Visit 1)\]. * serum alkaline phosphatase (ALP) \> 2 × ULN * mean platelet count \< 50,000/mm3 * total bilirubin ≥ 2.0 mg/dL (subjects with a documented history of Gilbert's syndrome can be enrolled if the direct bilirubin is within normal reference range) * model for end-stage liver disease (MELD) score ≥12 * Child-Turcotte-Pugh (CTP) Score ≥7 Note: Following Phase 2b, subjects with CTP scores ≥7 may be enrolled if recommended\* by the Data Safety Monitoring Board (DSMB) and approved by the Trial Steering Committee (TSC), based on the planned interim analysis (IA). \[\*based on DSMB review of preliminary results from a separate hepatic impairment clinical trial (Study GT-032) which is assessing belapectin safety and pharmacokinetic (PK) in cirrhotic subjects with CTP scores ≥7. * estimated glomerular filtration rate \< 45 mL/min\* \*Note: per Modification of Diet in Renal Disease algorithm 10. Taking an angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, or β-1 selective adrenergic receptor inhibitor, unless on a stable regimen for at least 3 months prior to Screening and no changes in the regimen are anticipated during the study. Subjects taking a non-selective beta blocker are not eligible to be enrolled (Investigators are encouraged to substitute another medication, if clinically warranted). 11. History of major surgery during Screening. 12. History of a solid organ transplant requiring immunosuppressive therapy. 13. History of bariatric surgery within 1 year of randomization, or plan to undergo bariatric surgery during the study. 14. Has positive screening test for illicit drugs of abuse at Screening. 15. Has participated in an investigational new drug study within 30 days or 5 half-lives whichever is longer, prior to randomization. 16. Has a history of malignancy within 5 years of randomization, except for basal cell carcinoma, squamous cell carcinoma, and adequately treated in situ uterine cervical cancer. 17. Has clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring intervention (eg, pacemaker/ablation) or Grade II or greater peripheral vascular disease. 18. Has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurological, psychiatric, gastrointestinal, systemic inflammatory, metabolic or endocrine disorder or any other condition that, in the opinion of the Investigator, renders the subject a poor candidate for inclusion into the study. 19. Has known allergies to the IMP or any of its excipients. 20. Has previously received belapectin within 6 months of randomization. 21. Is an employee or family member of the Investigator or study center personnel.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease portal hypertension esophageal varices prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis NASH - nonalcoholic steatohepatitis Prevention of esophageal varices

Contacts and locations

Locations

AZ Maria Middelares

Ghent, VOV, 9000, Belgium
Advanced Pharma CR, LLC

Miami, Florida, 33147, United States
Antwerp University Hospital

Edegem, Antwerpen, 2650, Belgium
Arizona Liver Health - Glendale

Glendale, Arizona, 85306, United States
Associates in Gastroenterology

Hermitage, Tennessee, 37067, United States
Baylor College of Medicine - Baylor Clinic - Abdominal Transplant & Liver Disease Clinic

Houston, Texas, 77030, United States
Bon Secours Liver Institute of Virginia - Newport News

Newport News, Virginia, 23602, United States
Bon Secours Liver Institute of Virginia - Richmond

Richmond, Virginia, 23226, United States
Box Hill Hospital

Box Hill, Victoria, 3128, Australia
Brampton Civic Hospital

Brampton, Ontario, L6R 3J7, Canada
CEMDEC SA de CV Centro Mexicano de Desarrollo de Estudios Clinicos

Cuauhtémoc, Mexico City, 06100, Mexico
CHRU Montpellier - Saint Eloi

Montpellier, France, 34090, France
CHU Hôpital Henri Mondor

Créteil, France, 94000, France
CHU Nancy - Hôpital Brabois

Nancy, France, 54511, France
CHU de Grenoble

Grenoble, France, 38043, France
CHU de Nice - L'Archet

Nice, France, 6202, France
CICPA Centro de Investigación Clinica del Pacifico

Acapulco de Juárez, Guerrero, 39670, Mexico
California Liver Research Institute

Pasadena, California, 91105, United States
Carmel Medical Center

Haifa, 34362, Israel
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Centre Hospitalier Universitaire d'Amiens

Amiens, France, 80054, France
Centre Hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, H2X 0A9, Canada
Centro Especializado en Diabetes, Obesidad y Pevencion de enfermedades Cadiovasculares SC.

Miguel Hidalgo, Mexico City, 11650, Mexico
Centro de Investigacion Clinica de Oaxaca

Oaxaca City, Oaxaca, 68020, Mexico
Centro de Investigacion Medico Biologica y Terapia Avanzada SC

Guadalajara, Jalisco, 44130, Mexico
Centro de Investigaciones Clinicas Vina del Mar

Viña del Mar, CHL, 07081-2221, Chile
Centro de Investigaciones Metabólicas (CINME)

Capital Federal, ARG, C1056ABJ, Argentina
Centro de Investigación Medica de Aguascalientes

Aguascalientes, Aguascalientes, 20116, Mexico
ClinCloud LLC

Maitland, Florida, 32751-3320, United States
Clinique Universitaire De Bruxelles Hôpital Erasme VZW

Brussels, BEL, 1070, Belgium
Clínica Universidad de los Andes

Santiago, CHL, 7550000, Chile
Columbia University Medical Center

New York, New York, 10032, United States
Complexo Hospitalario Universitario de Pontevedra

Pontevedra, Spain, 36071, Spain
Consultants for Clinical Research

Cincinnati, Ohio, 45249, United States
Consultorio Medico

Ciudad de Mexico, State of Mexico, 6700, Mexico
Cumberland Research Associates, LLC

Fayetteville, North Carolina, 28304-3571, United States
Digestive Health Specialists

Dothan, Alabama, 36305, United States
Digestive Healthcare of Georgia, P.C.

Atlanta, Georgia, 30309, United States
Digestive Research Alliance of Michiana, LLC

Incheon, 400-711, South Korea
EUGASTRO GmbH

Leipzig, Saxony, 4103, Germany
East Tennessee Research Institute - Gastrointestinal Associates of Northeast Tennessee, P.C.

Johnson City, Tennessee, 37604-6063, United States
Excel Clinical Research - Las Vegas

Las Vegas, Nevada, 89109-6209, United States
Fiona Stanley Hospital

Murdoch, Western Australia, 6150, Australia
Florida Medical Center & Research

Zephyrhills, Florida, 33542, United States
Florida Research Institute

Lakewood Rch, Florida, 34211, United States
Fundacion de Investigacion de Diego

San Juan, Puerto Rico, 00927, Puerto Rico
Galen Medical Group - Ziegler Plaza

Chattanooga, Tennessee, 37343-5470, United States
Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park

Germantown, Tennessee, 38138, United States
Gastroenterology Associates of Central Georgia, LLC

Macon, Georgia, 31201, United States
Gastroenterology Associates of Fredericksburg

Fredericksburg, Virginia, 22401-8425, United States
Gastroenterology Associates of Western Michigan

Wyoming, Michigan, 49519, United States
Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, 30060, United States
Genoma Research Group, Inc.

Miami, Florida, 33165, United States
Goethe-Universität Frankfurt am Main

Frankfurt am Main, Germany, 60590, Germany
Groupe sante CHC - Clinique du MontLegia

Liège, WLG, 4000, Belgium
Guardian Angel Health Services, Inc.

Tampa, Florida, 33614, United States
Hadassah Ein Karem Hospital

Jerusalem, 91120, Israel
Hanyang University Seoul Hospital

Seoul, KOR, 4763, South Korea
Henry Ford Health System - Hemophilia and Thrombosis Treatment Center

Detroit, Michigan, 48202, United States
Holy Family Hospital

Nazareth, 16100, Israel
Hope Clinical Research, Inc.

Canoga Park, California, 91303, United States
Hospital Británico de Buenos Aires

Buenos Aires, ARG, C1280AEB, Argentina
Hospital Clínico Universidad de Chile

Santiago, 8380000, Chile
Hospital Italiano de Buenos Aires

Buenos Aires, ARG, C1181ACH, Argentina
Hospital Universitario 12 de Octubre

Madrid, ESP, 28041, Spain
Hospital Universitario Dr. Jose Eleuterio Gonzalez Servicio de Gastroenterología

Monterrey, Nuevo León, 64460, Mexico
Hospital Universitario La Paz

Madrid, Spain, 28046, Spain
Hospital Universitario Marqués de Valdecilla

Santander, Spain, 39008, Spain
Hospital Universitario Puerta de Hierro - Majadahonda

Majadahonda, Spain, 28222, Spain
Hospital Universitario Ramón y Cajal

Madrid, Spain, 28034, Spain
Hospital Universitario Virgen del Rocío

Seville, Spain, 41013, Spain
Hospital de La Serena

La Serena, CHL, 1710216, Chile
Hospital del Mar Research Institute

Barcelona, Spain, 8003, Spain
Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, 23249-0001, United States
Hôpital Avicenne

Bobigny, France, 93000, France
Hôpital Cochin

Paris, France, 75014, France
Hôpital de la Croix-Rousse

Lyon, France, 69004, France
Hôpitaux Universitaires de Strasbourg - Hôpital Civil

Strasbourg, France, 67091, France
ID Clinic

Mysłowice, Silesian Voivodeship, 41-400, Poland
IU Health University Hospital

Indianapolis, Indiana, 46202, United States
Impact Research Institute

Waco, Texas, 76710-2582, United States
Inland Empire Liver Foundation

Rialto, California, 92377, United States
Institute for Liver Health - Tucson

Tucson, Arizona, 85712, United States
Integrity Clinical Research, LLC (ICR SITES) - Doral

Doral, Florida, 33166, United States
Investigacion Biomedica para el desarrollo de farmacos SA de CV

Zapopan, Jalisco, 45070, Mexico
Investigacion Biomedica para el desarrollo de farmacos SA de CV

Benito Juárez, Mexico City, 03103, Mexico
Kansas City Research Institute

Kansas City, Missouri, 64131, United States
Kansas Medical Clinic PA

Topeka, Kansas, 66606, United States
King's College Hospital NHS Foundation Trust

London, GBR, SE5 9RS, United Kingdom
Liver Specialists of Texas

Austin, Texas, 78757, United States
Liver Wellness Center - Little Rock

Little Rock, Arkansas, 72205-6414, United States
Loyola University Health System

Maywood, Illinois, 60153, United States
Lucas Research

Morehead City, North Carolina, 28557, United States
MEDIVEST Centro de Investigacion integral

Chihuahua City, Chihuahua, 31203, Mexico
Mayo Clinic Hospital - Florida

Jacksonville, Florida, 32224-1865, United States
Medical Care and Research SA de CV

Mérida, Yucatán, 97070, Mexico
Medical University of Lodz

Lodz, Łódź Voivodeship, 91-347, Poland
Medical University of South Carolina (MUSC)

Charleston, South Carolina, 29425, United States
Medyczny Katedra i Klinika Chorób Zakaźnych, Chorób Wątroby i Nabytych Niedoborów Odpornościowych

Wroclaw, Poland, 50-220, Poland
Mercy Medical Center - The Institute for Digestive Health and Liver Disease

Baltimore, Maryland, 21202, United States
Methodist Transplant Physicians

Dallas, Texas, 75203, United States
Michiana Gastroenterology, Inc.

South Bend, Indiana, 46635, United States
Monash Medical Centre Clayton

Clayton, Victoria, 3168, Australia
Mount Sinai Beth Israel

New York, New York, 10003, United States
NYU Langone Medical Center

New York, New York, 10016-6402, United States
Nature Coast Clinical Research, LLC

Inverness, Florida, 34452, United States
Nepean Hospital

Kingswood, New South Wales, 2750, Australia
NewYork-Presbyterian Hospital/Weill Cornell Medical Center

New York, New York, 10021, United States
Oaxaca Site Management Organization SC.

Oaxaca City, Oaxaca, 68000, Mexico
Om Research LLC

Lancaster, California, 93534, United States
Pacific Gastroenterology Associates

Vancouver, British Columbia, V6Z 2K5, Canada
Peak Gastroenterology Associates

Colorado Springs, Colorado, 80907-6262, United States
Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Pinnacle Clinical Research

San Antonio, Texas, 78229, United States
Pioneer Research Solutions Inc - Houston - Stancliff Rd

Houston, Texas, 77099, United States
Rabin Medical Center - Beilinson Hospital

Petah Tikva, 4941492, Israel
Rambam Medical Center

Haifa, 3109601, Israel
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
SP CSK im Prof. Kornela Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach

Katowice, Silesian Voivodeship, 40-752, Poland
Sensible Healthcare

Ocoee, Florida, 34761, United States
Soroka Medical Center

Beersheba, 84101, Israel
South Texas Research Institute

Edinburg, Texas, 78539, United States
Southern California GI & Liver Centers

Coronado, California, 92118, United States
Southern Therapy and Advanced Research (STAR) - Jackson

Jackson, Mississippi, 39216, United States
Tandem Clinical Research, LLC

Marrero, Louisiana, 70072, United States
Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel
Texas Clinical Research Institute, LLC

Arlington, Texas, 76012, United States
Texoma Liver Center PLLC. - Denison

Denison, Texas, 75020, United States
The Chaim Sheba Medical Center - The Center for Liver Diseases

Ramat Gan, 52621, Israel
The Institute for Liver Health

Chandler, Arizona, 85224, United States
The Jefferson Digestive Health Institute - Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
The Texas Liver Institute, Inc.

San Antonio, Texas, 78215, United States
The University of Nottingham - Nottingham Digestive Diseases Centre Biomedical Research Unit

Nottingham, NGM, NG7 2UH, United Kingdom
Toronto Liver Centre

Toronto, Ontario, M6H 3M1, Canada
Tufts Medical Center

Boston, Massachusetts, 02111-1552, United States
Tulane Cancer Center

New Orleans, Louisiana, 70112-2600, United States
UNC-Chapel Hill School of Medicine

Chapel Hill, North Carolina, 273302, United States
Universitair Ziekenhuis Gent

Ghent, VOV, 9000, Belgium
Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Mainz, Rhineland-Palatinate, 55131, Germany
University Diabetes & Endocrine Consultants

Chattanooga, Tennessee, 37411, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44016, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of Calgary - Heritage Medical Research Clinic - Foothills Hospital Center

Calgary, Alberta, T2N 4Z6, Canada
University of California San Diego Medical Center -La Jolla Multi-Specialty Clinics- Perlman Offices

La Jolla, California, 92037, United States
University of Cincinnati Physicians Company, LLC

Cincinnati, Ohio, 45267-0595, United States
University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States
University of Louisville Physicians - Cardiovascular Medicine Physicians Outpatient Center

Louisville, Kentucky, 40202-2046, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center (UPMC) - The Center for Liver Diseases

Pittsburgh, Pennsylvania, 15213, United States
University of Utah Health Care - UUHC - Kidney & Liver Clinic

Salt Lake City, Utah, 84132-0001, United States
University of Virginia School of Medicine

Charlottesville, Virginia, 22908, United States
Velocity Clinical Research, Spokane

Spokane, Washington, 99202-3462, United States
Yonsei University, Wonju Severance Christian Hospital

Seoul, KOR, 8308, South Korea
Yonsei University, Wonju Severance Christian Hospital

Wŏnju, KOR, 26426, South Korea
inSite Digestive Health Care - Orange

Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.